

Microsoft Bing

国内版 国际版

First-line Pazopanib in Patients with Advanced Non-Clear Cell Renal

Chat with Bing

Sign in

ALL IMAGES VIDEOS

0,710 Results Any time

First-Line PAzopanib in NON-clear-cell Renal cArcinoMA ...
<https://www.sciencedirect.com/science/article/pii/S1558767316303706>
Cited by: 22 Author: Sebastiano Buti, Melissa Bersanelli, Francesc...
Publish Year: 2016
Aug 01, 2017 · Introduction. Non-clear-cell renal carcinoma (nccRCC) is a widely heterogeneous disease, for which treatment is based merely on minor evidence, such as retrospective analyses, small...

First-line pazopanib in non-clear cell renal carcinoma ...
https://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.e16081
Cited by: 22 Author: Sebastiano Buti, Melissa Bersanelli, Francesc...
Publish Year: 2016
Background: Pazopanib is a standard first line treatment for metastatic clear cell renal cell carcinoma (RCC). Very few data on its activity in non-clear cell RCC (nccRCC) are currently available in the ...

See more

ALL IMAGES VIDEOS

8,090 Results Any time

First-line pazopanib in non-clear cell renal carcinoma ...

https://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.e16081

Background: Pazopanib is a standard first line treatment for metastatic clear cell renal cell carcinoma (RCC). Very few data on its activity in non-clear cell RCC (nccRCC) are currently available in the literature. We retrospectively analyzed the efficacy and toxicity of Pazopanib in an Italian multicenter cohort of nccRCC patients.

Cited by: 22 Author: Sebastiano Bufi, Melissa Bersanelli, France...
 Publish Year: 2016

First-Line Pazopanib in Non-clear-cell Renal cArcinoMA ...

<https://www.sciencedirect.com/science/article/pii/S1558767316303706>

Aug 01, 2017. Introduction. Non-clear cell renal carcinoma (nccRCC) is a widely heterogeneous disease, for which treatment is based merely on minor evidence, such as retrospective analyses, small phase II randomized and non-randomized studies, and subgroup analyses of expanded access programs (EAPs), or perspective trials including mixed histology. 1 The current recommendation for treating ...

Cited by: 22 Author: Sebastiano Bufi, Melissa Bersanelli, France...
 Publish Year: 2016

PEOPLE ALSO ASK

- Which is first line non clear cell renal carcinoma? ▾
- Are there clinical trials for cabozantinib in renal cell carcinoma? ▾
- What kind of disease is renal cell carcinoma? ▾

Feedback

Safety and Efficacy of Pazopanib in First-Line Metastatic ...

<https://www.sciencedirect.com/science/article/pii/S155876731830096X>

Feb 01, 2019. Pazopanib has been approved for first-line treatment of patients with metastatic renal-cell carcinoma on the basis of clinical trials that enrolled only patients with adequate renal function. Few data are available on the safety and efficacy of pazopanib in patients with renal insufficiency.

Cited by: 5 Author: Cristina Masini, Maria Giuseppa Vitale, Mar...
 Publish Year: 2019

IPOR Pazopanib as a possible option for the treatment of ...

<https://journals.sagepub.com/doi/full/10.1177/175095900145002>

Pazopanib

Common brand name: Votrient

Side effects Warnings Interactions Dosage >

Pazopanib is used to treat kidney cancer. It may also be used to treat certain other types of cancer.

Precautions

Side Effects Interactions Warnings

Brand names: Votrient

Drug classes: Protein kinase inhibitor Antineoplastic Agent

Pregnancy category: Consult a doctor

Availability: Prescription needed

People also search for

- sunitinib
- axitinib
- sorafenib
- cabozantinib
- regorafenib

See more ▾

Data from First Databank and others. [Learn more](#)

Consult a medical professional for advice

[Suggest an edit](#)

Search Tools



Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 65078

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series

Buti S *et al.* Pazopanib in advanced non-clear cell renal carcinoma

Sebastiano Buti, Melissa Bersanelli, Francesco Massari, Ugo De Giorgi, Orazio Caffo, Gaetano Aurilio, Umberto Basso, Giacomo Carteni, Claudia Caserta, Luca Galli, Francesco Boccardo, Giuseppe Procopio, Gaetano Facchini, Giuseppe Fornarini, Alfredo Berruti, Elena Fea, Emanuele Naglieri, Fausto Petrelli, Roberto Iacovelli, Camillo Porta, Alessandra Mosca

Abstract

BACKGROUND

Match Overview

Rank	Source	Words	Similarity
1	Crossref: Sebastiano Buti, Melissa Bersanelli, Francesca Massari, Gaetano Facchini et al. "First-Line Pazopanib in Non-clear ..."	92 words	3%
2	Crossref: David F. McInerney, Jee-Lyuh Lee, Marek Zlobin, Cristina Suarez et al. "Open-Label, Single-Arm, Phase II Study ..."	29 words	1%
3	Internet: link.springer.com	17 words	1%
4	Crossref: Dominique Boncheblin, Philippe Barthélémy, "Cabozantin ... a new first-line option for papillary renal cell carcinoma?"	15 words	1%
5	Internet: repositorio.pucrs.br	15 words	1%
6	Internet: sc.scripps.edu	15 words	1%
7	Internet: www.x-mol.com	15 words	1%
8	Crossref: Alessandra Mosca, Ugo De Giorgi, Giuseppe Procopio, Umberto Basso et al. "An Italian, multicenter, real-world, ret ..."	14 words	1%
9	Crossref: Abbiges, Laurence, and Bernard Escudier. "Current and future strategies in nonclear cell metastatic renal cell carcinoma: A review"	15 words	<1%
10	Internet: 特别设置以适配 Windows ...	13 words	<1%

国内版 国际版

First-line pazopanib in patients with advanced non-clear cell renal



ALL IMAGES VIDEOS

4,610 Results Any time ▾

[First-line pazopanib in non-clear cell renal carcinoma ...](#)

https://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.e16081

Background: Pazopanib is a standard first line treatment for metastatic clear cell renal cell carcinoma (RCC). Very few data on its activity in non-clear cell RCC (nccRCC) are currently available in the literature. We retrospectively analyzed the efficacy and toxicity of Pazopanib in an Italian multicenter cohort of nccRCC patients.

Cited by: 24 Author: Sebastiano Buti, Melissa Bersanelli, Fran...

Publish Year: 2016

[First-Line PAZopanib in NON-clear-cell Renal cArcinoMA ...](#)

<https://www.sciencedirect.com/science/article/pii/S1558767316303706>

Aug 01, 2017 · Pazopanib is a standard first-line treatment for metastatic clear-cell renal cell carcinoma (ccRCC). Very few data on its activity in non-clear-cell renal cell carcinoma (nccRCC) are currently available. The aim of this study was to retrospectively analyze efficacy and toxicity of pazopanib in nccRCC patients.

Cited by: 24 Author: Sebastiano Buti, Melissa Bersanelli, Fran...

Publish Year: 2016

People also ask

Which is first line non clear cell renal carcinoma? ▾

Are there clinical trials for cabozantinib in renal cell carcinoma? ▾

What kind of disease is renal cell carcinoma? ▾

Feedback

[Real-world evidence on first-line treatment for metastatic ...](#)

<https://ecancer.org/en/journal/article/973-real...> ▾

< **Abstract** Introduction Methods Results Discussion Con >